about
Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.Pharmacotherapy of haemophilia A.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.Emerging therapies for hemophilia: controversies and unanswered questions.Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
P2860
Q34099771-4F5E4320-F4C5-4F23-A3D0-C5F7C938B4A7Q34283156-D17B5C86-8206-46E3-8503-398A621B98C0Q35793113-2AC779B5-7D48-4C29-92C0-C6802830C97BQ36480548-836EF3E8-BFD6-4496-ACF5-4928B7491AEEQ36912731-7E351D21-E34F-4F42-A536-732FF27DAACDQ37686530-E732FFE1-A498-4F21-AD16-E21F3778FAA4Q37891089-3271A28E-B998-45E9-94CF-1509216F85AEQ38205211-DE66E8AB-70B3-43AA-B244-B3EBB28BFB30Q38764214-8ACE6FE8-DD47-440F-9295-C57648F433D1Q42220577-EC3D7624-F237-4B1D-9894-CA66D2D431F1Q42611760-0A72958C-F185-40FE-BAEA-D7BAC3DE5750Q42681561-16F28530-D848-4A67-99D9-15921031C6EDQ45866709-D2A8A95E-1E79-40DF-8A9F-B06ACF2F5158Q45866906-33B86CE9-8FFF-4CDD-A46E-1E1921C3D452Q45869833-77A9C286-86AA-40A5-BBC1-0AEBED7E549AQ45882434-80853549-9826-4B9E-9844-82483B4ADF0BQ45887781-25BAFBD6-C9E9-45D6-B333-966E68063AD8Q54958581-D953C576-3AB7-4C0A-A380-28F8665BE898Q55313906-4236937F-5808-4CCE-98D2-624B3514238C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Pharmacokinetics of factor VIII and factor IX.
@ast
Pharmacokinetics of factor VIII and factor IX.
@en
type
label
Pharmacokinetics of factor VIII and factor IX.
@ast
Pharmacokinetics of factor VIII and factor IX.
@en
prefLabel
Pharmacokinetics of factor VIII and factor IX.
@ast
Pharmacokinetics of factor VIII and factor IX.
@en
P2860
P1433
P1476
Pharmacokinetics of factor VIII and factor IX.
@en
P2093
P2860
P304
94-9; discussion 100
P356
10.1046/J.1365-2516.9.S1.8.X
P478
P577
2003-05-01T00:00:00Z